[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568887":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":44,"responsibleParty":64,"collaborators":25,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":25,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":25,"enrollmentInfo":75,"targetDuration":25,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":47,"whyStopped":25,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Ascentage Pharma Group Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"APG -2449 Monotherapy","EXPERIMENTAL","Part A: Monotherapy for advanced solid tumors.",[13],"Drug: APG -2449",{"label":15,"type":10,"description":16,"interventionNames":17},"APG -2449 combined with PLD","Part B: Dose exploration and expansion of APG-2449 combined PLD.",[13,18],"Drug: PLD",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","APG -2449","Orally once a day(QD), every 28 days as a cycle.",[9,15],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"PLD","Injected on the first day of each cycle, every 28 days as a cycle.",[15],[31],{"name":32,"affiliation":33,"role":34},"Jundong Li, M.D.","Sun Yat-sen University","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Yifan Zhai, M.D., Ph.D.","CONTACT","+86-20-28068501","yzhai@ascentage.com",{"name":42,"role":38,"phone":25,"phoneExt":25,"email":43},"Wentao Pan, Ph.D.","Wentao.Pan@ascentage.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Sun Yat-sen University Cancer Center","RECRUITING","Guangzhou","Guangdong","510060","China","CN",{"type":54,"coordinates":55},"Point",[56,57],113.25,23.11667,{"lat":57,"lon":56},[60,63],{"name":32,"role":38,"phone":61,"phoneExt":25,"email":62},"020-87343292","lijd@sysucc.org.cn",{"name":32,"role":34,"phone":25,"phoneExt":25,"email":25},{"type":65,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100568887","phase-1-apg-2449-monotherapy-or-in-combination-with-pld-in-patients-with-platinum-resistant-recurrent-oc-or-advanced-st-100568887",false,"NCT06687070","APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST","A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APG-2449 Monotherapy or in Combination With Anticancer Agents in Patients With Platinum-resistant Recurrent Ovarian Cancer or Advanced Solid Tumors","Inclusion Criteria:\n\n1. Part A: No gender limitation. Patients with histologically and\u002For cytologically confirmed ALK\u002FROS1 gene fusion positive non-small cell lung cancer and various advanced tumors.\n\n   Part B: Female only. Histologically proven ovarian epithelial, fallopian tube, or primary peritoneal carcinoma.\n2. At least one measurable tumor lesion.\n3. ECOG score is 0\\~1.\n4. Life expectancy of ≥3 months.\n5. AE caused by previous treatment must recover to ≤ grade 1.\n6. Sufficient bone marrow, liver, kidney and coagulation function.\n7. Female patients must be in a non-pregnant and non-lactating state.\n8. Able to understand and willing to sign informed consent.\n9. Patients are required to provide fresh or archived tumor tissue samples prior to treatment.\n\nExclusion Criteria:\n\n1. Undergone major surgery or major trauma within 28 days before first dose or a diagnostic biopsy within 14 days before first dose.\n2. Received systemic antitumor drugs, including investigational drugs.\n3. Received radiotherapy within 14 days before first dose.\n4. Previous treatment with FAK inhibitors.\n5. Have tumors at positions other than existing ovarian cancer or of other histological types within 3 years before first dose.\n6. Known active central nervous system (CNS) metastases and\u002For cancerous meningitis.\n7. Major cardiovascular and cerebrovascular disease occurred within 6 months before first dose.\n8. Patients with pleural effusion, pericardial effusion, or ascites requiring puncture, drainage, or having received drainage within 1 month before first dose.\n9. Malabsorption syndrome, or inability to take medications orally.\n10. Severe gastrointestinal disease.\n11. Any serious or uncontrolled systemic disease; Various chronic active infections.\n12. Allergy to APG-2449 or PLD and its drug components.\n13. Previous cumulative doses of anthracyclines ≥550 mg\u002Fm\\^2.\n14. Patients using a moderately potent CYP3A4, CYP2C9, or CYP2C19 inhibitor\u002Finducer or P-gp inhibitor within a week before first dose. Patients using CYP3A4 substrates and the drugs of a narrow treatment window within a week before first dose.\n15. Other factors that, in the investigator's judgment, should prevent the patient from entering the study.","ALL","18 Years",{"count":76,"type":77},50,"ESTIMATED","INTERVENTIONAL",[80],"PHASE1","An open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.",[83,84],"Platinum-resistant Recurrent Ovarian Cancer","Advanced Solid Tumor",[86],"APG-2449","2025-02-24",{"date":89,"type":90},"2025-02-26","ACTUAL",{"date":92,"type":90},"2024-12-17",{"date":94,"type":77},"2027-05",{"name":5,"class":6},1]